Tirbanibulin

KLISYRI

Open Tirbanibulin in the interactive console ↗

Pronunciation: tir-ban-i-BYOO-lin (klye-SI-ree)

Tirbanibulin ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Tirbanibulin ballicule

Tirbanibulin KLISYRI mascot mnemonic cartoon — Visual mnemonic: Tirbanibulin mascot
**“Kill, Siri...Tear beta tubulin”**

What it isA topical microtubule inhibitor ointment for actinic keratosis of the face and scalp.

Why this oneThe regimen is its selling point: once daily for five days, against weeks of irritation with older field therapies.

What limits itExpect a brief local reaction, and recurrence over time — field cancerization is managed, not cured.

Tirbanibulin molecular structure (skeletal formula) — Molecular structure: Tirbanibulin

FDA label

Read the full label on DailyMed ↗

FDA dosing	Population	Start	Target	Max
Actinic keratosis of the face or scalp	Adults	Topical: apply QD to treatment field (up to 100 cm2) on face or balding scalp, 1 unit-dose packet per application	Topical QD x 5 consecutive days (single course)	Topical QD x 5 days; up to 100 cm2 field

Renal Undefined

Hepatic Undefined

Instructions

Topical use only; not for oral or ophthalmic use
Wash hands immediately with soap and water after application
Avoid washing or touching the treated area for ~8 h after application; afterwards may wash with mild soap
Avoid transfer to periocular area; avoid application near mouth and lips
Avoid use until skin has healed from any previous drug, procedure, or surgical treatment
Occlusion after application increases irritation

Available strengths

ointment 1 %

Cautions

Ophthalmic adverse reactions: eye irritation on accidental ocular exposure — flush with water and seek medical care
Local skin reactions, including severe (vesiculation/pustulation, erosion/ulceration), in the treated area

Adverse reactions

Local skin reactions: erythema (91%), flaking/scaling, crusting, swelling
Application site pain (10%)
Application site pruritus (9%)
No contact sensitization, phototoxicity, or photoallergy in dermal safety studies

Pregnancy No human data; oral tirbanibulin in animals caused fetal deaths/malformations at >=19x MRHD exposure

Lactation No data on transfer to human or animal milk; weigh benefits of breastfeeding vs maternal need

Cost

Tirbanibulin (KLISYRI)

Strength		#/mo	generic $/unit	CostPlus
1 %	ointment	per unit		not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Tirbanibulin is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

NO BOXED WARNINGS

Classes and tags

Clinical profile

Therapeutic safety burden0 / 4

Overdose danger1 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Legacy pregnancy categoryN/A (post-2015 labeling)

Defining liabilityLocal inflammatory skin reactions and eye irritation

Open Tirbanibulin in the interactive console ↗